Consistent with the mouse data, the expression levels of MET in clinical samples exhibited a negative correlation with the relative abundance of most tumor-infiltrating lymphocytes (TILs) (Fig. 2a), major histocompatibility complexes (MHCs) (Fig. 2b), immunomodulators (Fig. 2c), and chemokines (Fig. 2d) in liver hepatocellular carcinoma (LIHC). This evidence concerns the gene MET and neoplasm.